Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a specific focus on transdermal technologies, today announced it has been engaged by and received a first order from Fit For Life Group (“FFL”), a major brand license holder. Nutriband expects a fully executed supplier agreement to follow. Under the agreement Nutriband’s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer. “This purchase order from FFL allows Nutriband and our contract manufacturing subsidiary, Active Intelligence, to once again demonstrate our capabilities in the development and manufacturing of innovative products,” said Gareth Sheridan, CEO of Nutriband. “We are excited to continue to showcase Active Intelligence’s capabilities and innovation by partnering with some of the world’s largest brands.”
To view the full press release, visit https://ibn.fm/0MJYW
About Nutriband Inc.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse deterrent fentanyl patch incorporating its AVERSA(TM) abuse-deterrent technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. For more information about the company, visit www.Nutriband.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, announced the issuance of…
NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, will release its financial results for the…
HeartBeam (NASDAQ: BEAT) a medical technology company advancing personalized cardiac care, has appointed Chief Executive…
HealthLynked (OTCQB: HLYK) today announced a major enhancement to its appointment booking capabilities, further expanding…
TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an…
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a $4.3 million New Drug Application filing…